The First-in-class Bispecific Antibody IBI318 (LY3434172) Targeting PD-1 and PD-L1 in Patients with Advanced Tumors: a Phase Ia/Ib Study
Journal of Hematology & Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined